Addex Therapeutics Return on Equity (ROE) Growth & History (ADXN)
Addex Therapeutics's return on equity was −93.16% for fiscal 2025.
View full Addex Therapeutics company overviewAddex Therapeutics annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −93.16% | −223.55 pp |
| 2024 | 2024-12-31 | 130.39% | +478.87 pp |
| 2023 | 2023-12-31 | −348.48% | −158.00 pp |
| 2022 | 2022-12-31 | −190.48% | −93.13 pp |
| 2021 | 2021-12-31 | −97.35% | −33.27 pp |
| 2020 | 2020-12-31 | −64.08% | −18.43 pp |
| 2019 | 2019-12-31 | −45.64% | −37.54 pp |
| 2018 | 2018-12-31 | −8.11% | — |
Addex Therapeutics quarterly return on equity
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q1 2026 | 2026-03-31 | −42.51% | −26.12 pp |
| Q4 2025 | 2025-12-31 | −34.26% | — |
| Q3 2025 | 2025-09-30 | −23.95% | — |
| Q2 2025 | 2025-06-30 | −23.74% | — |
| Q1 2025 | 2025-03-31 | −16.39% | — |
| Q2 2023 | 2023-06-30 | −48.47% | — |
Addex Therapeutics return on equity trends
Over the last five fiscal years, Addex Therapeutics's return on equity decreased from −64.08% to −93.16%, a change of −29.08 percentage points. The latest reported quarter, Q1 2026, shows −42.51%.
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Addex Therapeutics source filings ↗